{"schema_version":"1.0","type":"article","title":"諾和諾德大三期慘敗！6,300 人的教科書級教訓","url":"https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure.md","lang":"zh-Hant","date":"2026-08-13","publish_at":"2026-08-13T08:00:00+08:00","updated_at":"2026-08-13","category":"商業分析系列","topic":"商業分析系列","tags":["Novo Nordisk","ziltivekimab","ZEUS","MACE","IL-6","hsCRP","心血管","慢性腎臟病","NVO","合一生技"],"summary":"ZEUS 超過 6,300 人卻交出 HR 0.99：ziltivekimab 壓低 free IL-6 與 hsCRP，卻沒有證明能降低三點 MACE。這不是抗發炎假說死亡，而是 biomarker 不能替患者硬終點預支成功。","key_points":[],"facts":[],"sections":["01｜二期明星，三期翻車","02｜第二期有多漂亮？幾乎把發炎指標打穿","03｜三種指標，一定要分開看","04｜ZEUS 為什麼失敗？目前只有兩個假說","05｜漂亮數字翻車，心血管史上早有前例","06｜看到漂亮的第二期，先問這三題","結語｜前面每一張漂亮圖，都只是前提","參考資料"],"references":[{"title":"[Novo Nordisk，ZEUS 第三期結果]","source":"","date":"","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916587"},{"title":"[ZEUS 登錄]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT05021835"},{"title":"[RESCUE]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/34015342/"},{"title":"[ILLUMINATE]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa0706628"},{"title":"[PROMINENT]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/36342113/"},{"title":"[STABILITY]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1315878"},{"title":"[VISTA-16]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/24247616/"},{"title":"[NORVIT]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa055227"},{"title":"[CANTOS]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1707914"},{"title":"[LoDoCo2]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2021372"}],"images":[{"alt":"圖1｜ZEUS 超過 6,300 人、HR 0.99，發炎指標下降但三點 MACE 未降低","url":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/figure-01.png"},{"alt":"圖2｜RESCUE 與 ZEUS 回答不同問題，二期 biomarker 不能直接外推三期硬終點","url":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/figure-02.png"},{"alt":"圖3｜風險標誌物、藥效學標誌物與替代終點是三種不同證據層級","url":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/figure-03.png"},{"alt":"圖4｜ZEUS 目前已知、未知與不能外推的結論邊界","url":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-13）。諾和諾德大三期慘敗！6,300 人的教科書級教訓。https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-13-ziltivekimab-zeus-mace-phase3-failure-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}